An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Branaplam (Primary) ; Branaplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 19 Aug 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.